Pulmonary function after hematopoietic stem cell transplantation is significantly better in pediatric recipients following reduced toxicity compared with myeloablative conditioning.
Department of Pediatrics, Columbia University, New York, NY, USA.
R
R
Majzner
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
C
C
Sandoval
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
A J
AJ
Dozor
Department of Biostatistics, Columbia University, New York, NY, USA.
Z
Z
Jin
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
C
C
van de Ven
Department of Pediatrics, Columbia University, New York, NY, USA.
R
R
Dalal
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
E
E
Morris
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
L
L
Harrison
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
K
K
Wolownik
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
S
S
Fabricatore
Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
L A
LA
Baxter-Lowe
Department of Pediatrics, New York Medical College, Valhalla, NY, USA.|Department of Medicine, New York Medical College, Valhalla, NY, USA.|Department of Pathology, New York Medical College, Valhalla, NY, USA.|Department of Microbiology & Immunology, New York Medical College, Valhalla, NY, USA.|Department of Cell Biology & Anatomy, New York Medical College, Valhalla, NY, USA.
M S
MS
Cairo
D000293:Adolescent; D000328:Adult; D002066:Busulfan / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000592:standards; D006801:Humans; D008171:Lung Diseases / Q000209:etiology; D008297:Male; D019653:Myeloablative Agonists / Q000627:therapeutic use; D012129:Respiratory Function Tests / Q000379:methods*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods* / Q000592:standards; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use; D055815:Young Adult
D019653:Myeloablative Agonists; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine